Bioactive secondary metabolite production from endophytic fungi has gained a recurring research focus in recent decades as these microorganisms represent an unexplored biological niche for their diverse biotechnological potential. Despite this focus, studies involving tropical endophytes remain scarce, particularly those isolated from medicinal plants of these ecosystems. In addition, the state of the art of the pharmaceutical industry has experienced stagnation in the past 30years, which has pushed pathogenic infections to get one step ahead, resulting in the development of resistance to existing treatments. Here, five fungal endophytes were isolated from the medicinal plant Otoba gracilipes (Myristicaceae), which corresponded to the genera Xylaria and Diaporthe, and screened to demonstrate the promissory potential of these microorganisms for producing bioactive secondary metabolites with broad-spectrum antibacterial activities. Thus, the evaluation of crude organic extracts obtained from the mycelia and exhaust medium allowed the elucidation of Xylaria sp. and Diaporthe endophytica potential toward providing crude extracellular extracts with promising bioactivities against reference strains of Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923), according to the determined half-maximum inhibitory concentration (IC₅₀) with values down to 3.91 and 10.50mg/ml against each pathogen, respectively. Follow-up studies provided insights into the polarity nature of bioactive compounds in the crude extracts through bioactivity guided fractionation using a polymeric resin absorbent alternative extraction procedure. In addition, evaluation of the co-culturing methods demonstrated how this strategy can enhance endophytes biosynthetic capacity and improve their antibacterial potential with a 10-fold decrease in the IC₅₀ values against both pathogens compared to the obtained values in the preliminary evaluations of Xylaria sp. and D. endophytica crude extracts. These results support the potential of Colombian native biodiversity to provide new approaches concerning the global emergence of antibiotics resistance and future production of undiscovered compounds different from the currently used antibiotics classes and simultaneously call for the value of preserving native habitats due to their promising ecosystemic applications in the biotechnological and pharmaceutical industries.

近几十年来，从内生真菌中生产生物活性次生代谢物已成为反复研究的焦点，因为这些微生物因其多样化的生物技术潜力代表了一个尚未开发的生物生态位。尽管有这个重点，涉及热带内生菌的研究仍然很少，特别是那些从这些生态系统的药用植物中分离出来的。此外，过去 30 年制药行业的技术水平停滞不前，这推动了病原体感染向前迈进了一步，导致对现有治疗方法产生了耐药性。在这里，从药用植物中分离出五种内生真菌羽扇豆 （肉豆蔻科），对应于属 木兰 和 迪亚波特，并进行筛选以证明这些微生物具有产生具有广谱抗菌活性的生物活性次级代谢物的潜力。因此，对从菌丝体和排气介质中获得的粗有机提取物的评估允许阐明木兰sp. 和内生菌 提供具有针对参考菌株的有希望的生物活性的粗细胞外提取物的潜力 大肠杆菌 (ATCC 25922) 和 金黄色葡萄球菌(ATCC 25923)，根据测定的半最大抑制浓度 (IC ₅₀ )，对每种病原体的值分别低至 3.91 和 10.50mg/ml。后续研究通过使用聚合物树脂吸收剂替代提取程序的生物活性引导分馏，提供了对粗提取物中生物活性化合物极性性质的见解。此外，对共培养方法的评估证明了该策略如何增强内生菌的生物合成能力并提高其抗菌潜力，与初步评估中获得的值相比，对两种病原体的 IC ₅₀值降低了 10 倍。木兰sp. 和内生菌粗提取物。这些结果支持哥伦比亚本土生物多样性的潜力，可以为全球出现抗生素耐药性和未来生产与目前使用的抗生素类别不同的​​未发现化合物提供新方法，同时呼吁保护原生栖息地的价值，因为它们有前景的生态系统应用生物技术和制药行业。